Northern Trust Corp Moleculin Biotech, Inc. Transaction History

Northern Trust Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.9 - $1.34 $6,542 - $9,740	7,269 Added 15.69%	53,596 $51,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $2.0 $5,240 - $8,808	-4,404 Reduced 8.68%	46,327 $67,000
Q1 2021 May 12, 2021	BUY	$3.7 - $6.42 $187,704 - $325,693	50,731 New	50,731 $207,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $72.7M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.